## **18th Meeting of the Directors of NMIs and Member States Representatives** October 24-25, 2016 BIPM, France

Metrological Methodologies in the Health Sector, Chair – Willie E. May

## **Presentations**

- NIST programs to address next Generation healthcare and forensic science Willie E. May, NIST challenges
- Developing chemistry and biology programs in Korea Sang Roul Park, KRISS
- Health challenges facing the developing world Dinesh Aswal, NPL (India)
- Trace Element Analysis in Food
- Panel discussion and debate

Takashi Usuda, NMIJ






## **18th Meeting of the Directors of NMIs and Member States Representatives** October 24-25, 2016 BIPM, France

# **NIST Programs to Address Next Generation Healthcare** and Forensic Science Challenges

- **October 25, 2016**
- Dr. Willie E. May
- U.S. Under Secretary of Commerce for Standards and Technology &
  - **Director, National Institute of Standards and Technology**

National Institute of Standards and Technology





In addition to maintaining the more traditional National Physical Measurement Standards, we also focus a significant portion of our research and measurement services activities on addressing contemporary societal needs



## **NIST has become:**

- an ever increasing number of areas

1901


## Supporting the Industrial Revolution



**Interoperability of fire** hose screw threads



Light bulb standards




**Standards for irons and** steels



Working with ICC to reduce railway accidents

## a key player on the Administration's Innovation Team

the nation's go-to agency for measurements, standards, and technology in







- Traditional Clinical Diagnostics Tests
- Personalized Medicine/Genetics-Directed Therapy

- and Regulatory Approval of Biosimilars
- **Energy- Absorbing/Dissipating Materials**
- **U.S. Judicial System**

# Topics

# **Measurement Science, Tools, and Standards to Support the Manufacture**

# **National Head Health Challenge to Stimulate Development of Innovative**

## Improving the Science that Underpins the Forensic Evidence used in the

## Healthcare reform is a major issue throughout the world

- The rising cost of healthcare and increased prevalence of chronic diseases is having a devastating affect of economic security and quality of life in all parts of the world.
- Major efforts are underway to reform healthcare and reduce spending through increased efficiency and quality, focusing on prevention of disease and creating a healthier population.
- It is a stated goal of the Obama Administration to improve the quality of U.S. health care while lowering its cost by computerizing all Americans' medical records. ... "this will cut waste, eliminate red tape, and reduce the need to repeat expensive medical tests .... it will save lives by reducing the deadly but preventable medical errors that pervade our health care system".
  - Need interoperable health IT network that is correct, complete, secure, usable, and testable

**Measurements** that are comparable over space and time are key to achieving these Global and National Goals


# Healthcare reform is a major issue throughout the world

## ~\$3 trillion spent annually in U.S. on healthcare of which 10% -15% is based on measurements • 70% of healthcare decisions are based on results from clinical laboratory measurements

- Bias in measurements affects medical decision-making

### **Cholesterol Frequency Distribution of >20,000 Mayo Clinic Patients**


(with +1%, +3% and +10% limits around 240 mg/dL criteria point)



Cholesterol, mg/dL

If measurement	Positives (>240 mg/dL) Predicted Change				
<u>bias were:</u>	<u>per 1000</u>	in "Positives/1000"			
-10% bias	120	-129			
-3% bias	203	<b></b>			
-1% bias	234	<b>-15</b>			
0% bias	249				
+1% bias	263	+ <b>1</b> 4			
+3% bias	300	+51			
+10% bias	446	+197			

**NIST Cholesterol-in-Blood Experiment -Impact of Inaccurate Measurements** 








# Lack of Specificity Can Cause Problems

- the bloodstream after myocardial damage
- **Measurement Challenges:** 
  - Low levels of detection needed: 0.1 20 ng/mL
  - troponin subunits, degradation in serum)



Cardiac Troponin I is a heart muscle protein that is observed in

• Heterogeneity of troponin forms (phosphorylation, complexation with other

Conc. ng/mL	# Labs			
19.9	115			
6.7	<b>489</b>			
0.85	27			
enver Health and Hospitals ommunication 1997				

# The Questions are Different for.... Measurements:


- >37,000 deaths annually in U.S. from prostate cancer
- Blood tests for PSA are used to screen for the likelihood of prostate cancer
- PSA is a heterogeneous protein that occurs both free and complexed
- Immunoassays are the approach favored for routine measurement of PSA
- Wide variability among the results from immunoassays (see below)
- High incidence of false positives and false negatives

# of Labs	- Low -	- Med	-High-	-Mean-	- S.D		95% Confidence <b>Range</b>
2672	10.8	19.4	34.5	19.67	2.14	10.9	15.39-23.95
2653	7.2	9.8	18	9.92	1.11	11.2	7.70-12.14
2689	5.3	7.3	12.8	7.36	0.79	10.7	5.78-8.94
2509	2.1	3	4.7	3.03	0.33	10.8	2.37-3.69
2504	0.6	0.7	1.5	0.73	0.11	14.5	0.51-0.95
2591	0.1	0.2	0.8	0.24	0.1	40.2	0.04-0.44

From: http://www.cooleyville.com/cancer/capsava.htm

## **NIST** has provided Standards for Healthcare Measurements for more than 90 years

## It is congruent with the NIST mission - and indeed our mandate - to address the measurement and standards barriers affecting the cost and quality of healthcare delivery




1920's - Today: Program in Radiation Physics initially focused on dosimetry standards for X-ray calibration, now includes standards for mammography, brachytherapy, and radionuclides for radiopharmaceuticals

diagnostics



# **Making Medical Imaging Digital – not Analog**

- (optical and magnetic) radiation medical imaging technologies to promote reproducibility, reduce uncertainty associated with various imaging modalities.
- **GE Healthcare PET-MRI scanner.**



**NIST MRI Phantoms** 

• Standards, phantoms, and improved contrast agents for ionizing and non-ionizing

## First commercially-available traceable PET phantoms to be shipped with every



# **Personalized Medicine**



"Doctors have always recognized that every patient is unique, and doctors have always tried to tailor their treatments as best they can to individuals. You can match a blood transfusion to a blood type — that was an important discovery. What if matching a cancer cure to our genetic code was just as easy, just as standard? What if figuring out the right dose of medicine was as simple as *taking our temperature?" President Obama, January 30, 2015* 

## Personalized Medicine requires use of information and data from a patient's genotype and phenotype (level of gene expression and/or other clinical information) to:

- stratify disease
- select a medication
- provide a therapy

## Personalized Medicine can address questions of the common man/woman -

- Why do adverse drug reactions and interactions occur in some people and others not? •
- Can I be sure that I am getting the right treatment for me ullet
- Can I be sure that the generic protein drug that I get will work the same as the more expensive name brand drug?

initiate a preventative measure that is particularly suited to that patient at the time of administration






## **Genetics Directed Therapy**



## Normal Cell Nuclei

False positive



http://online.wsj.com/article/SB119941325367266813.html



"The College of American Pathologists and the American Society of Clinical Oncology have estimated that around 20% of HER-2 testing may be inaccurate"

## **Get Herceptin unnecessarily**

- Expensive ullet
- Numerous side effects  $\bullet$


## Herceptin Treatment withheld

- Inappropriate treatment
- Increased morbidity
- Increased mortality

## Impact of NIST-developed Certified Reference Material for HER2

## In response to the need for better accuracy for HER2 testing


- NIST developed Standard Reference Material 2373 "Genomic DNA Standards for HER2 Measurements"
  - Scientists at the Frederick Cancer Institute evaluated the usefulness of SRM 2373 for ensuring the accuracy of measurements of HER2 gene copy numbers.
  - They reported in the new issue of the Journal of **Molecular Diagnostics**, that the use of SRM 2373 as a QA tool led to increased confidence in HER2 amplification measurements in a clinical setting



Three-dimensional culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green. The cancer in these cells is driven by the HER2 gene (also known as ErbB2).

Credit: NCI Center for Cancer Research National Cancer Institute, National Institutes of Health





## What's needed to implement personalized medicine more broadly?

Linking outcome of genomics, proteomics, metabolomics, microbiome measurements and imaging data to a specific disease state

## **Providing Confidence in Genomics Measurements: Genome in a Bottle**

**NIST led consortium with more than 75 public, private, academic partners** 

- Developed "RM 8398 Human DNA for Whole-Genome Variant **Assessment**" to provide quality assurance of whole genome sequencing technologies
- Use this Standard facilitated FDA approval of results from highthroughput DNA sequencing

"The federal government opened a new era of genetic medicine on Thursday by introducing a standard way to ensure the accuracy of DNA tests used to tailor treatments for individual patients." NY Times (5/14/15)

Ability to put all of these sources together to determine what are most important factors or combination of factors that link to disease and predict outcome of therapies

Big data analytics, models







# **Biologic Drugs**

- ulletthe U.S.
- The global biologics market is estimated to grow to ~\$380 B by 2019 from \$200 B in 2013 (BCC Research), - These "biologic drugs" are not synthesized chemically, but rather are made in bioreactors using living cells
- However, they are very expensive and generics are not widely available in the U.S.
  - Globally, biologics with estimated sales of \$100 billion will come off patent protection by 2020

NIST was asked by both FDA and the industry to apply its unique combination of expertise in the physical, chemical, and the biological measurement sciences to underpin the development and regulatory approval of followon biologic/biosimilar drugs





Small chemical molecule 800-1000 Da **Produced via chemical synthesis** 


Note: relative scale is illustrative

Calcitonin Simple Biologic 3455 Da, ~32 Amino acids **Produced in yeast, bacteria** 

The Cost of Protein therapeutics is one of the fastest growing components to the overall cost of health care in

# These drugs have proven to be very therapeutic and substantially improve patients' health and quality of life.





Monoclonal Antibody (IgG) **Complex Biologic** 150,000 Da, ~1300 Amino acids (with host cell modifications) **Produced in mammalian cells** 







# **Examples of Biologic Drugs and Their Sales**

## World-wide Biologic Mark estimated to exceed \$350B by 2019


## **2014 US sales**

Humira Lantus Enbrel Remicade Neulasta Rituxan Avastin Herceptin Epogen

rheumatoid arthritis diabetes rheumatoid arthritis rheumatoid arthritis chemotherapy infections cancer cancers breast cancer anemia due to chronic kidney disease ~\$2.0 billion

http://www.marketwatch.com/story/biosimilarsfollow-on-biologics-market-is-expected-to-reach-35-billion-globally-by-2020-2014-07-21 1. The Economics of Biosimilars by Blackstone and Fuhr (2013) American Health and Drug Benefits. Vol. 6, No 8

~\$10.7 billion ~\$5.5 billion ~\$4.4 billion ~\$3.9 billion ~\$3.6 billion ~\$3.6 billion ~\$2.9 billion ~\$2.2 billion



## **Program Areas:**

- **1.** Protein structure: higher order structure, post-translational modifications
  - "Structural Sameness" of the manufactured biopharmaceutical
- 2. Measurements & standards for protein stability, aggregation, & particles
  - •
- 3. Measurement tools & science to understand production cell variability



# **Metrology for Biomanufacturing**

Measurement science, tools & standards to support manufacturing & regulatory approval of biologic drugs



# **Propensity** of the biopharmaceutical to induce an Immune Response in Patients

# **Complex Inner Workings of Cells** used in the production of Biologic Drugs

**Congressional Subcommittee Hearing - Need for Measurement Standards to Facilitate R&D of Biologic** Drugs, Sept. 2009 Dr. Anthony Mire-Sluis (Amgen) (From L to R): Dr. Patrick VJJ Vink (Mylan)


Dr. Steven Kozlowski (FDA) Dr. Willie E. May (NIST)

# **NIST Partnership in Head Health Challenge III**

## Stimulate development of innovative energy absorbing and dissipating materials **Materials Innovations of Finalists**




- **\$250,000 to 5 finalists** to advance performance of their innovative materials over 2016.
- Winner will receive \$500,000 **Grand Prize** in February 2017.



"Architected" Impact Absorbers

**Measurement Challenges Addressed through parallel NIST Research:** 

- *Metrology:* Materials energy absorption in shear address brain injuries from rotation
- **Modelling:** Of the innovative "architected" materials HHCIII finalists produced (w/CHiMAD)
- Standards: Test methods for energy absorbing materials under multiaxial deformation



NIST testing of finalist materials will help determine the HHCIII Grand Prize Winner



## First-Round Awardees: Head Health Challenge III -**Advanced Materials for Impact Mitigation**

- Alba Technic, LLC (Winthrop, Maine)
- **Charles Owen Inc.** (Lincolnton, Ga.)
  - material with a stacked, origami-like design can fold efficiently to optimize energy absorption.
- **Corsair Innovations** (Plymouth, Mass.)
  - a textile that uses tiny, spring-like fibers to repel rotational and linear impacts,
- **Dynamic Research Inc.** (Torrance, Calif.) and **6D Helmets LLC** 
  - 6D's single-impact suspension technology is being evolved for use in repeated impact conditions.
  - order to reduce the effect of both angular and linear impact forces.
- **University of Michigan** (Ann Arbor, Mich
  - a lightweight, multi-layered composite that includes a viscoelastic material.
  - material can be uniquely utilized to help limit the force of multiple and repeated impact events.

patented, shock-absorbent honeycomb material with an outer layer that diverts the energy from a fall or hit. upon impact, the outer layer changes into a hard shell to spread the energy and protect the user from injury.

material based on originally developed for applications such as solar array packing for space industry.

- is washable, breathable, wicks sweat and can be easily engineered to meet impact performance requirements.

- 6D's multi-layer, suspended internal liner system allows the outer layer to move independently of the inner layer in


# HHCIII Testing Facilities: Linear Impact Tests

## **Materials Response to Linear Impact:**

- Instrumented drop tower
- Sports-level Impacts: 7.5 J to 75 J range
- Energy/Momentum Transfer through Material

## **Instrumented Drop Mass**

- 3.3 kg (tunable)
- 2 triaxial accelerometers
- 127 mm radius Impactor (NOCSAE)
- Force transducer: force transmitted through impactor




"Direct" Injury

# Energy In (Mass, velocity) ↓ Deceleration ↑ Duration ↑ Duration Minimize Energy Transfer (↓ Force and Momentum)

Role of protective

material

NIST drop tower



## **HHCIII Materials Test Regimen:**

Stepped Impacts with increasing drop height:

Energy/rate dependence of performance

Performance Degradation:

- Multiple impacts @ 60 J, and
- Conditioned with 1200 cycles quasi-static loading


Temperature Dependence

Conditioned at 0°C & 40°C

# New Capability: Shear Impact Test


- Material energy absorption under shear impact (w/compression)
- Key to reducing rotational momentum in sports impacts
- First data collected this summer


Shear load can be quasi-static or impact



Instrument Design

## Rotational/Shear Injury





## New NIST instrument

# **Changes in Needs/Expectations in Rigor for Forensic Evidence**

- Forensic science is in a period of changing expectations and requirements in the U.S.
  - expectations of forensic science laboratories.

## In the News

# The Washington Post

## National accreditation board suspends all DNA testing at D.C. crime lab

## A wake-up call on the junk science infesting our courtrooms

Washington Post, September 20, 2016

 There is growing concern about the scientific foundation, measurement rigor, and statistical validity of many forensic analyses that is leading to renewed attention to how scientific data are presented in evidentiary settings as well as to




# The New York Eimes Fix the Flaws in **Forensic Science**







# **Status of Forensic Science in U.S.**





**REPORT TO THE PRESIDENT** Forensic Science in Criminal Courts: **Ensuring Scientific Validity** of Feature-Comparison Methods

> Executive Office of the Presiden President's Council of Advisors on Science and Technology

> > September 2016



## **2009 U.S. National Academy of Science Report**

- - **Area Committees (OSAC)**

## 2016 President's Council of Advisors on Science & Technology (PCAST) Report

- system
- - methods
  - for a number of forensic "feature-comparison" methods

"With the exception of nuclear DNA analysis, no forensic method has been rigorously shown to have the capacity to consistently, and with a high degree of certainty, demonstrate a connection between evidence and a specific individual or source." (p.7)

[It] also criticized the 21 Scientific Working Groups advising the forensics jurisprudence community as being "too highly fragmented with very different structures and outputs . . .the resulting standards were not enforceable or developed in an open and transparent manner. NIST responded in Feb 2013 with creation of a new entity – the **Organization of Scientific** 

President Obama asked PCAST, in 2015, as to whether there are additional steps on the scientific side, that could help ensure the validity of forensic evidence used in the Nation's legal

In Report to the President issued Sep 2016, Forensic Science in Criminal Courts: Ensuring Scientific Validity of Feature-Comparison Methods, PCAST identified two important gaps: the need for clarity about the scientific standards for the validity and reliability of forensic

the need to evaluate specific forensic measurement methods to determine whether they have been scientifically established to be valid and reliable. The study aimed to help close these gaps



# **Technical Merit of Forensic Science Methods**

## **PCAST report of Sept 2016 addresses:**

- **D** Bite Marks
- Footwear

# approach can be effective:

- DNA Mixtures
- Ballistics and Tool Marks
- Bite Marks

Special Issue(s) on "measurement science in forensics"

Firearms Latent fingerprints

- "NIST should take a leadership role in transforming three important feature-comparison methods that are currently subjective—latent fingerprint analysis, firearms analysis, and, under some circumstances, DNA analysis of complex mixtures—into objective methods<sup>\*</sup>
- Initial NIST efforts would look at three examples selected from different areas, as we learn if the

Discussions in progress between PCAST, NIST, and BIPM about having *Metrologia* provide



## **18th Meeting of the Directors of NMIs and Member States Representatives** October 24-25, 2016 BIPM, France

Metrological Methodologies in the Health Sector, Chair – Willie E. May

- Presentations
  - challenges Willie E. May, NIST Sang Roul Park, KRISS Dinesh Aswal, NPL (India) Takashi Usuda, NMIJ
  - NIST programs to address next Generation healthcare and forensic science Developing chemistry and biology programs in Korea Health challenges facing the developing world

  - Trace Element Analysis in Food
- Panel discussion and debate

